They suggest that only testing patients with certain features, including severe optic disc oedema or longitudinally extensive optic nerve lesions, amongst others, would increase the diagnostic yield of MOG tests and recommend that MOG testing should not be requested as part of routine screening for patients suspected of having MS due to a 0.3–2.5% false positive rate. The gene discussed is MOG; the disease is myeloid sarcoma.